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Abstract 
Background This study aimed to describe the epidemiologic characteristics of 
microscopic polyangiitis (MPA) and granulomatosis with polyangiitis (GPA) in Japan. 
Methods We used the database of Ministry of Health, Labour and Welfare (MHLW) 
from 2006 to 2008, and analyzed data of 938 patients (MPA=697, GPA=241) who had 
registered within one year after their onsets and fulfilled the MHLW diagnostic criteria. 
Results The mean ages of MPA and GPA patients were 69.4±0.4 and 58.4±1.1 years, 
respectively. Renal (86.9%), chest (73.7%) and nervous system (45.2%) symptoms were 
common in MPA patients. Ear, nose and throat (86.7%), chest (78.0%) and renal 
(60.6%) symptoms frequently observed in GPA patients. The concomitant 
cyclophosphamide (CY) usages with corticosteroids were observed in 22.2% of MPA 
patients and 58.5% of GPA patients. In multivariate analysis, the concomitant use of CY 
was associated with younger age and pulmonary hemorrhage in MPA patients and the 
avoidance of CY was associated with nervous system symptoms and rapidly progressive 
glomerulonephritis in GPA patients. Plasma exchanges were inducted in 5.2% MPA 
patients and 4.1% GPA patients. The addition of plasma exchange was associated with 
the elevation of serum creatinine level in patients with both MPA and GPA.  
Conclusion MPA dominancy and less frequency of renal involvement in GPA patients 
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may be significant feature in Japan. The clinical practice of MPA and GPA in Japan is 
characterized by less common use of CY and the employment of plasma exchange for 
the patients with deteriorated renal function. 
 
Key words anti-neutrophil cytoplasmic antibody (ANCA) associated vasculitis (AAV), 
cyclophosphamide, microscopic polyangiitis (MPA), plasma exchange, granulomatosis 
with polyangiitis (GPA) 
 
Introduction 
Microscopic polyangiitis (MPA) and granulomatosis with polyangiitis (GPA) are the 
most common forms of anti-neutrophil cytoplasmic antibodies (ANCA) associated 
diseases characterized by necrotizing small-vessel vasculitis (AAV). Approximately 
90% of patients with active, generalized MPA and GPA have circulating ANCA and 
such tight association raises the possibility of pathogenic roles of ANCA. The primary 
antigenic targets of ANCA are myeloperoxidase (MPO-ANCA) and proteinase-3 
(PR3-ANCA) of granulocytes and monocytes (1). MPA is characterized by frequent 
association of MPO-ANCA and pauci-immune necrotizing vasculitis without the 
granulomatous lesions; while GPA is characterized by high positive rate of PR3-ANCA 
and granuloma formations in various affected organs (2). 
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Previous report showed that the prevalence of MPA is higher than that of GPA in 
Japanese patients with renal vasculitis while GPA is much more common in Europe (3). 
They also reported that the older Japanese patients were more likely to be affected 
compared with European patients and significant differences in the profile of ANCA 
positivity. Although this report demonstrated the features of Japanese patients with renal 
vasculitis, the characteristics and status of Japanese patients with systemic vasculitis 
have been not clarified. In EULAR recommendation, a combination therapy with 
cyclophosphamide (CY) and corticosteroids for remission induction of systemic 
vasculitis and necessity of dose reduction for renal function and age was proposed (4). It 
remains unknown how often CY was used and what is the major determinant for the 
usage of CY in clinical practice for Japanese AAV patients. 
In Japan, MPA and GPA were recognized and officially certified as so called “the 
intractable diseases” by Ministry of Health, Labour and Welfare (MHLW). The patients 
recognized as MPA and GPA, who wish to receive public financial aid from MHLW 
covering medical costs, must sign agreements and submit applications. The patients 
certified according to MHLW diagnostic criteria of MPA or GPA (5)(6)(7) has been 
registered in MHLW database and their information, clinical characteristics, medical 
history, organ involvements, laboratory data, and modalities of treatments, were 
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digitally stored at the prefectural administrations and MHLW.   
We performed this study to survey the characteristics of Japanese patients with MPA 
and GPA based on data set of MHLW. We also attempted to investigate frequency of the 
concomitant use of CY or plasma exchange with corticosteroids, and determine the 
factors which contributed the choice of therapies for their inductions in MPA and GPA. 
 
Patients and Methods 
Studied patients. We were permitted to use data of 1320 patients (MPA=988, 
GPA=332) who were newly registered from 2006 to 2008 in MHLW database and 
whose clinical data input was completed electronically. Of 1320 patients, we identified 
1032 (MPA=787, GPA=246) patients, who had registered within one year after their 
onsets. Eventually we used the data of the 938 (MPA=697, GPA=241) patients fulfilled 
the above MHLW diagnostic criteria. The criteria of MPA indicate the following three 
symptoms; rapidly progressive glomerulonephritis (RPGN), pulmonary hemorrhage and 
other symptoms including purpura, subcutaneous hemorrhage, gastrointestinal bleeding, 
and mononeuritis multiplex. The patients were certified as definite MPA, who fulfill the 
following conditions; (1) positive for 2 or more of the symptoms, and positive 
histological findings, (2) Positive for 2 or more of the symptoms including the 
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symptoms RPGN and pulmonary hemorrhage, and positive MPO-ANCA. The 
conditions of probable MPA were (1) Positive for 3 of the symptoms, (2) Positive for 1 
of the symptoms, and positive MPO-ANCA(6). Of 697 MPA patients, 294 were 
diagnosed definitely and 403 were possibly. As GPA symptoms, the criteria have nose 
and throat (E), lung (L), kidney (K) and others due to vasculitis. Definite GPA mean the 
following; (1) Positive for 3 or more of the symptoms, including E, L, and K symptoms, 
(2) Positive for 2 or more of the symptoms, and positive for either of the histological 
findings, (3) Positive for 1 or more of the symptoms, positive for either of the 
histological findings, and positive PR3-ANCA/C-ANCA(7). Of 241 GPA patients, 168 
were diagnosed definitely and 73 were possibly. 
Data collection and arrangement. The following information was extracted from 
database: sex, age, the presence of histological examination, the histological findings, 
organ symptoms, ANCA positivity, the level of serum creatinine (Cr) and C-reactive 
protein (CRP), corticosteroid dosage, and concomitant usage of steroid pulse therapy, 
cyclophosphamide (CY) and plasma exchange or hemodialysis. We categorized organ 
symptoms into nine groups according to BVAS scoring system(8), which are “systemic 
symptoms”, “cutaneous symptoms”, “mucous membranes and eyes symptoms”, “ear, 
nose and throat symptoms”, “chest symptoms”, “cardiovascular symptoms”, 
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“abdominal symptoms”, “renal symptoms” and “nervous system symptoms”. We sorted 
each items of the database into these categories. For example, we defined the existence 
of systemic symptoms as at least one “yes” of the following items; fever (38°C or 
higher, 2 weeks or longer), body weight loss (6 kg or more for 6 months), myalgia 
/myositis and arthralgia /arthritis.  
Statistical analysis. After descriptive analysis of the characteristics and treatment 
status of the MPA and GPA patients, we compared the characteristics of patients with 
concomitant use of CY and corticosteroid alone. We calculated eGFR (estimated 
glomerular filtration rate) using the modification of diet in renal disease (MDRD) 
equation: 194.9×serum Cr-1.094.9× age-0.287 (×0.739 if women) (9). We categorized 
five groups according to eGFR and evaluated the correlation of these groups and CY 
usage in MPA and GPA by ANOVA. Similarly, in each disease category, we separated 
the subgroups with or without plasma exchange and compared their characteristics. In 
order to identify independent factors of concomitant usage of CY, the extracted 
variables in the univariate analysis were entered into multivariate analysis using the 
logistic regression model. All statistical analyses in this study were performed using the 
Statistical Package of JMP for Windows software, version 8.0 (SAS Institute Inc., Cary, 
NC, USA). Clinical variables with a possible relation to the outcomes were compared 
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by Mann-Whitney U and Chi-square tests (univariate model). All results were expressed 
as mean ± SE (standard error) and statistical significance was defined as a P-value of 
less than 0.05, two-tailed.  
 
Results 
Patient Characteristics of MPA and GPA (Table 1) 
We identified 697 MPA patients and 241 GPA patients. Patient characteristics are 
shown in Table 1. The mean age of MPA patients was 69.4±0.4 years and that of GPA 
patients was 58.4±1.1 years. Renal involvement was most frequently observed in MPA 
patients (86.9%) while ear, nose and throat (ENT) symptoms were most common in 
GPA patients (86.7%). Other major symptoms were systemic (80.3%), chest (73.7%) 
and nervous system involvements (45.2%) in MPA patients while systemic (81.3%), 
chest (78.0%), and renal involvements (60.6%) are frequent in GPA patients. 
MPO-ANCA or p-ANCA was positive in 97.1% of MPA patients and PR3-ANCA or 
c-ANCA was positive in 73.0% of GPA patients. All but excluding 5 patients with MPA 
and 7 patients with GPA were treated with corticosteroids and the mean maximum daily 
dosage of prednisolone was 26.5±0.9 mg/day in MPA patients and 35.3±1.6mg/day in 
GPA patients. The concomitant use of cyclophosphamide (CY) was seen 22.2% in MPA 
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patients and 58.5% in GPA patients. Plasma exchanges with MPA and GPA were 
performed in 5.2% and 4.1%, respectively. 
 
Characteristics of MPA and GPA patients treated with CY or corticosteroid alone 
(Tables 2 and 3) 
The patients treated with CY were significantly younger than corticosteroid alone in 
MPA patients (66.1±0.9 v.s. 70.1±0.5 years, p=0.0002) and GPA patients (57.2±1.4 
v.s.62.0±1.8 years, p=0.0395) . The concomitant CY usage was seen less frequently in 
GPA patients with lower eGFR significantly (Fig 1, p=0.014), although not significantly 
with MPA patients (Fig 1, p=0.370). The GPA patients who have RPGN or nervous 
system symptoms were treated with CY less frequently than corticosteroid alone. In 
contrast, MPA patients with cutaneous symptoms or pulmonary hemorrhage and GPA 
patients with ENT symptoms were treated with CY more frequently.  In the 
multivariate analysis included these extracted variables in the univariate analysis, age 
and pulmonary hemorrhage in MPA and nervous system symptoms and RPGN in GPA 
were independent factors for concomitant usage of CY (Table 4). The mean maximum 
daily dose of prednisone of the patients with CY were significant higher than the 
patients with corticosteroid alone in both MPA (32.6±1.9 v.s. 25.2±1.0 mg/day, 
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p=0.0008) and GPA patients (39.4±2.1 v.s. 29.5±2.5 mg/day, p=0.0025).  
 
Patient Characteristics of MPA and GPA treated with or without plasma exchange 
(Tables 5 and 6) 
The mean ages were similar between patients with plasma exchange and without 
plasma exchange in both MPA (68.6±1.9 v.s. 69.4±0.5 years, p=0.7041) and GPA 
patients (57.9 ±5.3 v.s. 58.5 ±1.1 years, p=0.9162). The patients who had treated with 
plasma exchange had pulmonary hemorrhages more frequently than those who treated 
without it in MPA (18.1 v.s. 8.2%, p=0.0009). The serum levels of Cr in the groups with 
plasma exchange was higher than those without plasma exchange both in MPA (3.8±
0.5 v.s. 2.4±0.1 mg/dl, p=0.0132) and GPA patients (3.7 ±0.8 v.s. 1.5 ±0.2, p=0.0102). 
Furthermore, the patients treated with plasma exchange had RPGN more frequently 
than those without it in GPA, and all of GPA patients with plasma exchange had renal 
symptoms. Similarly, dialysis treatment was more frequent in the patients with plasma 
exchange than those without plasma exchange in MPA patients (50.0% v.s. 9.8%, 
p<0.0001) and GPA patients (60.0% v.s. 4.3%, P<0.0001).  
 
Discussion 
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 We determined the characteristics and the current status of treatments for MPA and 
GPA based on the data set of MHLW database in Japan. In present study, the ratio of the 
patients with MPA and the patients with GPA was 3: 1. Watts et al. reported that the 
ratio of the MPA patients and GPA patients was 3 : 4 in UK(10). The predominance of 
MPA compared with GPA in Japan was similar to previous report (3) (11). The 
MPO-ANCA or p-ANCA positive MPA patients and PR3-ANCA or c-ANCA positive 
GPA patients were more common in this study. These results are consistent with 
previous Japanese nationwide epidemiological survey showed 87.3% MPA patients 
have p-ANCA positive and 85.7% WG patients have c-ANCA positive (11). Otherwise, 
western report showed 30.4% MPO-ANCA or p-ANCA positivity in MPA and 57.4% 
PR3-ANCA or c-ANCA positivity in GPA (12). MHLW criteria of MPA and GPA is 
consist of three parts; clinical symptoms, histological findings, and ANCA positivity. 
Especially MPA criteria contain MPO-ANCA or p-ANCA positivity while GPA criteria 
contain PR3-ANCA or c-ANCA positivity. There was no reference of ANCA in 
classification criteria of American College of Rheumatology (ACR) or Chapel Hill 
Consensus Conference. Although Watts et al. applied ANCA positivity to their 
classification algorithm, the type of ANCA is not taken into account in the diagnosis of 
MPA and GPA. Therefore these differences between MHLW criteria and other criteria 
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may affect the positivity of each ANCA in GPA and MPA in our study. In addition, the 
MHLW criteria emphasized specific clinical symptoms, such as RPGN and pulmonary 
hemorrhage, the study population may differ from previous reports. Considering the 
renal involvement represented only in 60% of patients with GPA in present study even if 
all items in renal symptom were included; while the glomerulonephritis represented in 
almost 80% of patients with GPA in their clinical course in USA(2). The patients within 
1 year from their disease onset were included in this study. In addition, the MHLW 
criteria of possible GPA need fewer clinical symptoms than the ACR criteria to 
diagnosis of GPA. Therefore more organ-limited type may be contained in this study 
population.  
The concomitant CY usage was less common option for treatment of AAV in the 
present study. Only 22% of patients with MPA and 59% of patients with GPA were 
treated with CY combined with corticosteroids, despite fact that several guidelines 
recommend the concomitant usage of CY for AAV (4, 13). Actually, 89 % of AAV 
patients were treated with CY combined with corticosteroids in previous European 
report(14). Even in Asian country, 94% of MPA patients were treated with a 
combination of CY and corticosteroids (15).  Japanese previous nationwide survey 
showed CY usage of 62.3% MPA and 96.3% GPA patients (11) and recent Japanese 
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patients with MPO-ANCA-associated vasculitis (JMAAV) study also reported 58.3% of 
patients were treated with CY(16). Therefore less CY usage might be characteristic of 
present Japanese therapy for AAV. In multivariate analysis, the avoidance of 
concomitant CY usages was associated with older age and pulmonary hemorrhage in 
MPA, RPGN and nervous system symptoms in GPA. The several guidelines recommend 
the reduction of the dosage of CY for elderly patients or deteriorated renal function in 
order to avoid the adverse effects (4, 13). Additionally a Japanese nationwide survey of 
RPGN reported that no additional benefit of immunosuppressants in elderly patients for 
the renal prognosis based on data for 715 RPGN patients collected  until  2001(17). 
Therefore the avoidance of concomitant usage rather than the proactive usage with dose 
reduction of CY for elderly patients and the patients with RPGN may be significant 
feature in current status of treatment for MPA in Japan. 
The maximum daily dose of corticosteroids was higher in patient with concomitant 
usage of CY than without those of CY. The common practice of the treatment of AAV 
patients is that the initial dose of corticosteroids has been continued for one month 
whereas more rapid tapering regimen of corticosteroids is adopted in several recent 
clinical trials (patients initially received 1 mg/kg/day of oral prednisolone, which was 
reduced to 0.75 mg/kg/day after 1 week, 0.50 mg/kg/d after 2weeks) (18-20).  Because 
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the body weight of patients with AAV was not registered in database and it was unable 
to assess in present study, the daily dose per body of corticosteroids could not be 
converted to dose per kilogram. But the patients of AAV are treated with about 0.8 
mg/kg/day of oral prednisolone commonly in Japan. Although the tapering speed of 
corticosteroids could not be assessed in present study, the patients with concomitant 
usage of CY may treated with higher dose of corticosteroid and tapered more rapidly as 
the regimen of recent clinical trials. 
In our study, about 5% patients were treated with plasma exchange. This result are 
similar to the JMAAV study that reported plasma exchange were procedure in only 2 of 
48 patients (16). Recent western study for remission maintenance showed that almost 
15% patients with AAV treated with plasma exchange and median levels of serum Cr 
was 2.9 or 2.7 mg/dl (18). The addition of plasma exchange was associated with the 
elevation of serum creatinine levels in patients with both MPA and GPA. The plasma 
exchange might be initiated based on renal dysfunction rather than disease 
classifications. The European randomized Methylprednisolone versus Plasma Exchange 
(MEPEX) trial showed that plasma exchange increased the rate of renal recovery in 
ANCA-associated systemic vasculitis that presented with renal failure (20). The 
EULAR recommendations propose the concomitant usage of plasma exchange for 
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patients with rapidly progressive severe renal disease based on this clinical trial (4). 
Because of less severe deterioration of renal functions in our population, the 
concomitant usage of plasma exchange might be less common. Among all chest 
symptoms, plasma exchange was performed for patients with pulmonary hemorrhage in 
our study. The British Society for Rheumatology and British Health Professionals in 
Rheumatology guidelines for vasculitis recommended that treatment with plasma 
exchange should be considered in patients with life-threatening manifestations of 
disease such as pulmonary hemorrhage as well as patients presenting with severe renal 
failure(13). 
Several limitations of present study should be noted. At first, we are not able to 
reconfirm the clinical data by checking medical records. Sakauchi et al. who studied the 
etiology of primary biliary cirrhosis using MHLW database pointed the similar 
limitation(21). In addition, we cannot discuss the reliability of data of the present study 
since this is the first report about the characteristics of MPA and GPA patients in Japan. 
Secondly, we applied to the MHLW criteria for diagnosis of MPA and GPA in present 
study; however the specificity and sensitivity of MHLW criteria have not been validated 
yet. Third, the choice of therapeutic modalities may be influenced by the healthcare 
access bias. At last, our investigation failed to demonstrate the association between 
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these treatments and prognosis since it was cross-sectional study. 
In conclusion, MPA dominancy and less frequency of renal involvement in GPA 
patients may be significant feature in Japan. The concomitant CY usage was less 
common for treatment of AAV in Japan. The plasma exchange was added to AAV 
patients with deteriorated renal function. Further investigations based on global 
definitions are required to further confirm these features in Japan.  
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Figure legend 
【Table 1】 Patient characteristics of MPA and GPA 
CY: cyclophosphamide, SE: standard error, Cr: creatinine, CRP: C-reactive protein, 
eGFR: estimated glomerular filtration rate, MPO-ANCA: myeloperoxidase 
anti-neutrophil cytoplasmic antibody, p-ANCA: perinuclear anti-neutrophil cytoplasmic 
antibody, PR3-ANCA: proteinase-3 anti-neutrophil cytoplasmic antibody, c-ANCA: 
cytoplasmic anti-neutrophil cytoplasmic antibody, PSL: prednisolone, m-PSL: methyl 
prednisolone 
 
【 Table 2 】  Characteristics of MPA patients treated with concomitant 
cyclophosphamide usage and corticosteroids monotherapy. 
CY: cyclophosphamide, CS: corticosteroids, SE: standard error, Cr: creatinine, eGFR: 
estimated glomerular filtration rate, CRP: C-reactive protein, MPO-ANCA: 
myeloperoxidase anti-neutrophil cytoplasmic antibody, p-ANCA: perinuclear 
anti-neutrophil cytoplasmic antibody, PR3-ANCA: proteinase-3 anti-neutrophil 
cytoplasmic antibody, c-ANCA: cytoplasmic anti-neutrophil cytoplasmic antibody, 
PSL: prednisolone, m-PSL: methyl prednisolone, *p<0.05 
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【Table 3】 Characteristics of GPA patients treated with concomitant cyclophosphamide 
usage and corticosteroids monotherapy. 
CY: cyclophosphamide, CS: corticosteroids, SE: standard error, Cr: creatinine, eGFR: 
estimated glomerular filtration rate, CRP: C-reactive protein, PSL: prednisolone, 
m-PSL: methyl prednisolone, *p<0.05 
 
【Table 4】 Logistic-regression analysis of independent factors of concomitant CY use 
ENT: Ear, nose and throat, eGFR: estimated glomerular filtration rate, RPGN: Rapidly 
progressive glomerulonephritis, *p<0.05 
 
【Table 5】 Patient characteristics of MPA treated with or without plasma exchange 
CY: cyclophosphamide, SE: standard error, Cr: creatinine, eGFR: estimated glomerular 
filtration rate, CRP: C-reactive protein, PSL: prednisolone, m-PSL: methyl prednisolone, 
*p<0.05 
 
【Table 6】 Patient characteristics of GPA treated with or without plasma exchange 
PE: plasma exchange, SE: standard error, Cr: creatinine, eGFR: estimated glomerular 
filtration rate, CRP: C-reactive protein, PSL: prednisolone, m-PSL: methyl prednisolone, 
*p<0.05 
 
【Fig 1】 The percentage of CY usages on each categories of  eGFR  
CY: cyclophosphamide, eGFR: estimated glomerular filtration rate, *p<0.05  
 
 
Table 1 Patient characteristics of MPA and GPA 
  MPA (n=697） GPA (n=241） 
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Diagnosis   
 Definite : possible 294 : 403 168 : 73 
Men : Women 299 : 398 139 : 102 
Age, mean ±SE years 69.4±0.4 58.4±1.1 
Symptoms   
 Systemic symptoms (%) 80.3 81.3 
 Cutaneous symptoms (%) 35.4 26.1 
 Mucous membrane and eyes (%) 13.1 46.1 
 Ear, nose and throat (%) 14.1 86.7 
 Chest (%) 73.7 78.0 
 Cardiovascular (%) 14.3 15.8 
 Abdominal (%) 10.2 7.1 
 Renal (%) 86.9 60.6 
 Nervous system (%) 45.2 32.3 
Pulmonary hemorrhage (%) 11.3 ND 
Rapidly progressive glomerulonephritis(%) 63.2 25.7 
Examination   
 Cr, mean ±SE (mg/dl) 2.5±0.1 1.6±0.2 
eGFR（ml/min./1.73m2） 43.2±1.3 75.3±3.2 
 CRP, mean ±SE (mg/dl) 9.0±0.3 10.2±0.5 
 MPO- or p-ANCA positive (%) 97.1 17.4 
 PR3- or c-ANCA positive (%) 7.0 73.0 
 Histological finding 30.6 52 
Treatment   
 Max. oral PSL dosage, mean ±SE mg/day 26.5±0.9 35.3±1.6 
 m-PSL pulse (%) 51.8 38.2 
 Immunosuppressants usage (%) 27.8 64.3 
 CY usage (%) 22.2 58.5 
 Plasma exchange (%) 5.2 4.1 
 Dialysis treatment (%) 11.9 6.6 
CY: cyclophosphamide, SE: standard error, Cr: creatinine, CRP: C-reactive protein, 
eGFR: estimated glomerular filtration rate, MPO-ANCA: myeloperoxidase 
anti-neutrophil cytoplasmic antibody, p-ANCA: perinuclear anti-neutrophil cytoplasmic 
antibody, PR3-ANCA: proteinase-3 anti-neutrophil cytoplasmic antibody, c-ANCA: 
cytoplasmic anti-neutrophil cytoplasmic antibody, PSL: prednisolone, m-PSL: methyl 
prednisolone 
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Table 2 Characteristics of MPA patients treated with concomitant cyclophosphamide 
usage and corticosteroids monotherapy. 
  
Concomitant 
CY usage 
(n=155） 
CS 
monotherapy 
(n=503） 
p 
Age, mean ±SE years 66.1±0.9 70.1±0.5 0.0002* 
Symptoms    
 Systemic (%) 81.9 80.0 0.6440 
  Cutaneous (%) 43.2 32.0 0.0120* 
  Mucous membrane and eyes (%) 11.6 13.0 0.7823 
  Ear, nose and throat (%) 15.5 13.4 0.5083 
  Chest (%) 74.8 73.0 0.6785 
  Cardiovascular (%) 11.0 14.8 0.2873 
  Abdominal (%) 12.9 9.4 0.2252 
  Renal (%) 85.8 87.2 0.6833 
  Nervous system (%) 45.8 44.2 0.7815 
Pulmonary hemorrhage (%) 18.1 8.2 0.0009* 
Rapidly progressive glomerulonephritis(%) 59.4 64.8 0.2518 
Cr, mean ±SE mg/dl 2.1±0.3 2.7±0.2 0.0635 
eGFR（ml/min./1.73m2） 48.0±2.7 41.8±1.5 0.0452* 
CRP, mean ±SE mg/dl 9.6±0.6 8.9±0.3 0.2763 
Max. oral PSL dosage, mean ±SE mg/day 32.6±1.9 25.2±1.0 0.0008* 
m-PSL pulse (%) 58.1 50.0 0.0813 
Plasma exchange (%) 9.7 3.8 0.0066* 
Dialysis treatment (%) 9.0 12.2 0.3146 
CY: cyclophosphamide, CS: corticosteroids, SE: standard error, Cr: creatinine, eGFR: 
estimated glomerular filtration rate, CRP: C-reactive protein, MPO-ANCA: 
myeloperoxidase anti-neutrophil cytoplasmic antibody, p-ANCA: perinuclear 
anti-neutrophil cytoplasmic antibody, PR3-ANCA: proteinase-3 anti-neutrophil 
cytoplasmic antibody, c-ANCA: cytoplasmic anti-neutrophil cytoplasmic antibody, 
PSL: prednisolone, m-PSL: methyl prednisolone, *p<0.05 
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Table 3 Characteristics of GPA patients treated with concomitant cyclophosphamide 
usage and corticosteroids monotherapy. 
  
Concomitant 
CY usage 
(n=141） 
CS 
monotherapy 
(n=86) 
p 
Age, mean ±SE years 57.2±1.4 62.0±1.8 0.0395* 
Symptoms    
  Systemic (%) 83.7 75.0 0.1566 
  Cutaneous (%) 26.2 26.3 1.000 
  Mucous membrane and eyes (%) 46.8 43.8 0.6760 
  Ear, nose and throat (%) 90.1 80.0 0.0421* 
  Chest (%) 80.9 75.0 0.3106 
  Cardiovascular (%) 13.5 23.8 0.0637 
  Abdominal (%) 6.4 7.5 0.7846 
  Renal (%) 59.6 61.3 0.8865 
  Nervous system (%) 27.0 45.0 0.0077* 
Rapidly progressive glomerulonephritis (%) 19.9 37.5 0.0065* 
Cr, mean ±SE mg/dl 1.5±0.2 1.8±0.3 0.4520 
eGFR（ml/min./1.73m2） 80.2±3.9 63.3±5.3 0.0106* 
CRP, mean ±SE mg/dl 10.6±0.7 9.3±0.9 0.2039 
Max. PSL dosage, mean ±SE mg/day 39.3±2.0 28.7±2.7 0.0018* 
m-PSL pulse (%) 39.0 41.3 0.7760 
Plasma exchange (%) 5.0 2.5 0.4933 
Dialysis treatment (%) 5.0 10.0 0.1711 
CY: cyclophosphamide, CS: corticosteroids, SE: standard error, Cr: creatinine, eGFR: 
estimated glomerular filtration rate, CRP: C-reactive protein, PSL: prednisolone, 
m-PSL: methyl prednisolone, *p<0.05 
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Table 4 Logistic-regression analysis of independent factors of concomitant CY use 
 
 Variable Odds Ratio (95%CI) P value 
MPA 
 Age (per yr) 
Pulmonary hemorrhage 
eGFR （ml/min./1.73m2） 
Cutanous 
0.97(0.96-0.99) 
2.76(1.61-4.71) 
1.00(1.00-1.01) 
1.40(0.94-2.09) 
0.0025* 
0.0003* 
0.1660 
0.0986 
GPA 
 Age (per yr) 0.99(0.97-1.00) 0.1889 
ENT symptoms 1.96(0.85-4.60) 0.1151 
Nervous system symptoms 0.48(0.26-0.88) 0.0174* 
RPGN 0.45(0.24-0.87) 0.0165* 
ENT: Ear, nose and throat, eGFR: estimated glomerular filtration rate, RPGN: Rapidly 
progressive glomerulonephritis, *p<0.05 
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Table 5 Patient characteristics of MPA treated with or without plasma exchange 
  PE  (n=36） 
non-PE  
(n=661） 
p 
Age, mean±SE years 68.6±1.9 69.4±0.5 0.7041 
Symptoms    
  Systemic (%) 69.4 80.9 0.1280 
  Cutaneous (%) 44.4 35.0 0.2835 
  Mucous membrane and eyes (%) 27.8 12.3 0.0178* 
  Ear, nose and throat (%) 16.7 13.9 0.6229 
  Chest (%) 83.3 73.2 0.2426 
  Cardiovascular (%) 25.0 13.8 0.0827 
  Abdominal (%) 8.3 10.3 1.0000 
  Renal (%) 97.2 86.4 0.0722 
  Nervous system (%) 33.3 45.8 0.1697 
Pulmonary hemorrhage (%) 36.1 10.0 <.0001* 
Rapidly progressive glomerulonephritis (%) 72.2 62.8 0.2902 
Cr, mean ±SE mg/dl 3.8±0.5 2.4±0.1 0.0132* 
eGFR（ml/min./1.73m2） 26.7±5.7 44.1±1.3 0.0031* 
CRP, mean ±SE mg/dl 12.2±1.1 8.8±0.3 0.0037* 
Max. oral PSL dosage, mean ±SE mg/day 23.5±4.2 26.7.±0.9 0.4580 
m-PSL pulse (%) 86.1 49.9 <.0001* 
CY usage (%) 41.7 21.2 0.0068* 
Dialysis treatment (%) 50.0 9.8 <.0001* 
CY: cyclophosphamide, SE: standard error, Cr: creatinine, eGFR: estimated glomerular 
filtration rate, CRP: C-reactive protein, PSL: prednisolone, m-PSL: methyl prednisolone, 
*p<0.05 
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Table 6 Patient characteristics of GPA treated with or without plasma exchange 
  PE  (n=10） 
non-PE  
(n=231） 
p 
Age, mean ±SE years 57.9±5.3 58.5±1.1 0.9162 
Symptoms    
  Systemic (%) 80.0 81.4 1.000 
  Cutaneous (%) 40.0 25.5 0.2931 
  Mucous membrane and eyes (%) 40.0 46.3 0.7566 
  Ear, nose and throat (%) 80.0 87.0 0.6262 
  Chest (%) 90.0 77.5 0.6958 
  Cardiovascular (%) 40.0 14.7 0.0547 
  Abdominal (%) 10.0 6.9 0.5258 
  Renal (%) 100.0 58.9 0.0071
*
 
  Nervous system (%) 50.0 31.6 0.3000 
Rapidly progressive glomerulonephritis (%) 60.0 24.2 0.0203
*
 
Cr, mean ±SE mg/dl 3.7±0.8 1.5±0.2 0.0102
*
 
eGFR（ml/min./1.73m2） 33.1±15.5 77.1±3.2 0.0058* 
CRP, mean±SE mg/dl 11.2±2.6 10.2±0.5 0.7008 
Max. oral PSL dosage, mean ±SD mg/day 20.0±8.4 35.9±1.6 0.0663 
m-PSL pulse (%) 90.0 35.9 0.0009
*
 
CY usage (%) 70.0 57.6 0.5268 
Dialysis treatment (%) 60.0 4.3 <.0001* 
PE: plasma exchange, SE: standard error, Cr: creatinine, eGFR: estimated glomerular 
filtration rate, CRP: C-reactive protein, PSL: prednisolone, m-PSL: methyl prednisolone, 
*p<0.05 
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